BioCardia (BCDA) 10-Q 9 Nov 22 2022 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 01, 2022
Document Information [Line Items]
Entity Central Index Key	0000925741
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	0-21419
Entity Registrant Name	BioCardia, Inc
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	23-2753988
Entity Address, Address Line One	320 Soquel Way
Entity Address, City or Town	Sunnyvale
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94085
City Area Code	650
Local Phone Number	226-0120
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		17,841,927
Warrant [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrant to Purchase Common Stock
Trading Symbol	BCDAW
Security Exchange Name	NASDAQ
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.001
Trading Symbol	BCDA
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 6,667	$ 12,872
Accounts receivable, net of allowance for doubtful accounts of $13 and $22 as of September 30, 2022 and December 31, 2021	300	147
Prepaid expenses and other current assets	187	462
Total current assets	7,154	13,481
Property and equipment, net	189	182
Operating lease right-of-use asset, net	1,664	1,883
Other assets	172	172
Total assets	9,179	15,718
Current liabilities:
Accounts payable	887	507
Accrued expenses and other current liabilities	2,115	2,121
Deferred revenue	378	847
Operating lease liability - current	304	237
Total current liabilities	3,684	3,712
Operating lease liability - noncurrent	1,398	1,631
Total liabilities	5,082	5,343
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value, 25,000,000 shares authorized and no shares issued and outstanding as of September 30, 2022 and December 31, 2021	0	0
Common stock, $0.001 par value, 100,000,000 shares authorized, 17,841,927 and 16,871,265 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively	18	17
Additional paid-in capital	141,655	139,055
Accumulated deficit	(137,576)	(128,697)
Total stockholders’ equity	4,097	10,375
Total liabilities and stockholders’ equity	$ 9,179	$ 15,718

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) -parentheticals (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Accounts Receivable, Allowance for Credit Loss, Current	$ 13	$ 22
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized (in shares)	25,000,000	25,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001	$ 0.001
Common Stock, Shares Authorized (in shares)	100,000,000	100,000,000
Common Stock, Shares, Issued (in shares)	17,841,927	16,871,265
Common Stock, Shares, Outstanding, Ending Balance (in shares)	17,841,927	16,871,265

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue:
Net product revenue	$ 212	$ 821	$ 1,246	$ 936
Costs and expenses:
Research and development	2,144	2,240	6,634	6,443
Selling, general and administrative	1,128	1,289	3,495	3,662
Total costs and expenses	3,272	3,529	10,129	10,105
Operating loss	(3,060)	(2,708)	(8,883)	(9,169)
Other income (expense):
Total other income, net	3	2	4	7
Net loss	$ (3,057)	$ (2,706)	$ (8,879)	$ (9,162)
Net loss per share, basic and diluted (in dollars per share)	$ (0.17)	$ (0.16)	$ (0.51)	$ (0.54)
Weighted-average shares used in computing net loss per share, basic and diluted (in shares)	17,844,991	17,066,068	17,523,837	16,867,652
Product [Member]
Revenue:
Net product revenue	$ 2	$ 1	$ 3	$ 1
Collaboration Agreement [Member]
Revenue:
Net product revenue	$ 210	$ 820	$ 1,243	$ 935

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at March 31, 2021 (in shares)	16,297,381
Balance at March 31, 2021	$ 16	$ 135,234	$ (116,074)	$ 19,176
Balance at December 31, 2020 (in shares) at Dec. 31, 2020	16,297,381
Balance at December 31, 2020 at Dec. 31, 2020	$ 16	135,234	(116,074)	19,176
Restricted stock units vested and issued (in shares)	40,100
Sale of common stock, net of issuance costs of $67 (in shares)	453,832
Sale of common stock, net of issuance costs of $67	$ 1	1,933		1,934
Exercise of common stock options (in shares)	1,580
Exercise of common stock options		5		5
Share-based compensation		416		416
Net loss			(2,969)	(2,969)
Balance at June 30, 2021 (in shares) at Mar. 31, 2021	16,792,893
Balance at June 30, 2021 at Mar. 31, 2021	$ 17	137,588	(119,043)	18,562
Balance at December 31, 2020 (in shares) at Dec. 31, 2020	16,297,381
Balance at December 31, 2020 at Dec. 31, 2020	$ 16	135,234	(116,074)	19,176
Net loss				(9,162)
Balance at June 30, 2021 (in shares) at Sep. 30, 2021	16,871,265
Balance at June 30, 2021 at Sep. 30, 2021	$ 17	138,631	(125,236)	13,412
Balance at March 31, 2021 (in shares)	16,792,893
Balance at March 31, 2021	$ 17	137,588	(119,043)	18,562
Balance at December 31, 2020 (in shares) at Mar. 31, 2021	16,792,893
Balance at December 31, 2020 at Mar. 31, 2021	$ 17	137,588	(119,043)	18,562
Restricted stock units vested and issued (in shares)	78,372
Share-based compensation		384		384
Net loss			(3,487)	(3,487)
Restricted stock units issued to settle management bonus obligations		214		214
Balance at June 30, 2021 (in shares) at Jun. 30, 2021	16,871,265
Balance at June 30, 2021 at Jun. 30, 2021	$ 17	138,186	(122,530)	15,673
Balance at March 31, 2021 (in shares)	16,871,265
Balance at March 31, 2021	$ 17	138,186	(122,530)	15,673
Share-based compensation		437		437
Net loss			(2,706)	(2,706)
Refund of issuance costs on sale of common stock	$ 0	8	0	8
Balance at June 30, 2021 (in shares) at Sep. 30, 2021	16,871,265
Balance at June 30, 2021 at Sep. 30, 2021	$ 17	138,631	(125,236)	13,412
Balance at March 31, 2021 (in shares)	16,871,265
Balance at March 31, 2021	$ 17	138,631	(125,236)	13,412
Balance at March 31, 2021 (in shares)	16,871,265
Balance at March 31, 2021	$ 17	139,055	(128,697)	10,375
Balance at December 31, 2020 (in shares) at Dec. 31, 2021	16,871,265
Balance at December 31, 2020 at Dec. 31, 2021	$ 17	139,055	(128,697)	10,375
Share-based compensation	$ 0	319	0	319
Net loss			(3,325)	(3,325)
Balance at June 30, 2021 (in shares) at Mar. 31, 2022	16,871,265
Balance at June 30, 2021 at Mar. 31, 2022	$ 17	139,374	(132,022)	7,369
Balance at December 31, 2020 (in shares) at Dec. 31, 2021	16,871,265
Balance at December 31, 2020 at Dec. 31, 2021	$ 17	139,055	(128,697)	$ 10,375
Exercise of common stock options (in shares)				0
Net loss				$ (8,879)
Balance at June 30, 2021 (in shares) at Sep. 30, 2022	17,841,927
Balance at June 30, 2021 at Sep. 30, 2022	$ 18	141,655	(137,576)	4,097
Balance at March 31, 2021 (in shares)	16,871,265
Balance at March 31, 2021	$ 17	139,374	(132,022)	7,369
Balance at December 31, 2020 (in shares) at Mar. 31, 2022	16,871,265
Balance at December 31, 2020 at Mar. 31, 2022	$ 17	139,374	(132,022)	7,369
Restricted stock units vested and issued (in shares)	311,929
Sale of common stock, net of issuance costs of $67 (in shares)	575,000
Sale of common stock, net of issuance costs of $67	$ 1	1,286		1,287
Share-based compensation		304		304
Net loss			(2,497)	(2,497)
Restricted stock units issued to settle management bonus obligations	$ 0	271	0	271
Balance at June 30, 2021 (in shares) at Jun. 30, 2022	17,758,194
Balance at June 30, 2021 at Jun. 30, 2022	$ 18	141,235	(134,519)	6,734
Balance at March 31, 2021 (in shares)	17,758,194
Balance at March 31, 2021	$ 18	141,235	(134,519)	6,734
Restricted stock units vested and issued (in shares)	17,029
Sale of common stock, net of issuance costs of $67 (in shares)	66,704
Sale of common stock, net of issuance costs of $67	$ 0	140	0	140
Share-based compensation		280		280
Net loss			(3,057)	(3,057)
Balance at June 30, 2021 (in shares) at Sep. 30, 2022	17,841,927
Balance at June 30, 2021 at Sep. 30, 2022	$ 18	141,655	(137,576)	4,097
Balance at March 31, 2021 (in shares)	17,841,927
Balance at March 31, 2021	$ 18	$ 141,655	$ (137,576)	$ 4,097

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited)-parentheticals (Parentheticals) - USD ($) $ in Thousands	3 Months Ended		15 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2021
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 1	$ 232	$ 67

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities:
Net loss	$ (8,879)	$ (9,162)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	61	45
Reduction in the carrying amount of right-of-use assets	219	418
Share-based compensation	903	1,237
Changes in operating assets and liabilities:
Accounts receivable	(153)	34
Prepaid expenses and other current assets	275	97
Other receivable due from related party	0	56
Accounts payable	380	100
Accrued expenses and other current liabilities	265	34
Deferred revenue	(469)	203
Operating lease liability	(166)	(453)
Net cash used in operating activities	(7,564)	(7,391)
Investing activities:
Purchase of property and equipment	(68)	(75)
Net cash used in investing activities	(68)	(75)
Financing activities:
Proceeds from sales of common stock	1,658	2,001
Issuance costs of sale of common stock	(231)	(59)
Proceeds from exercise of common stock options	0	5
Net cash provided by financing activities	1,427	1,947
Net change in cash and cash equivalents	(6,205)	(5,519)
Cash and cash equivalents at beginning of period	12,872	21,407
Cash and cash equivalents at end of period	6,667	15,888
Supplemental disclosure of noncash investing and financing activities:
Issuance of restricted stock units in lieu of cash bonus obligations	$ 401	$ 393

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) -parentheticals - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Accrued expenses and other current liabilities	$ 265	$ 34

Note 1 - Summary of Business an

Note 1 - Summary of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	(1) Summary of Business and Basis of Presentation (a) Description of Business BioCardia, Inc. (we, us, our, BioCardia or the Company), is a clinical-stage company focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. The Company’s lead therapeutic candidates are based on the CardiAMP Cell Therapy System, a platform which provides an autologous bone marrow derived cell therapy for treatment in two clinical indications: ischemic heart failure and refractory angina resulting from chronic myocardial ischemia. The Company’s second therapeutic platform is an investigational bone marrow derived allogeneic “off the shelf” Neurokinin-1 Receptor Positive mesenchymal stem cell therapy for the treatment of cardiac and pulmonary disease. To date, we have devoted substantially all our resources to research and development efforts relating to our therapeutic candidates and biotherapeutic delivery systems including conducting clinical trials, developing manufacturing and sales capabilities, in-licensing related intellectual property, providing general and administrative support for these operations and protecting our intellectual property. BioCardia also has three enabling device product lines: (1) the CardiAMP cell processing system; (2) the Helix biotherapeutic delivery system, or Helix; and (3) the Morph vascular access product line, or Morph. We manage our operations as a single segment for the purposes of assessing performance and making operating decisions.

Note 2 - Significant Accounting

Note 2 - Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	(2) Significant Accounting Policies (a) Basis of Preparation The accompanying condensed consolidated balance sheets, statements of operations, stockholders’ equity, and cash flows as of September 30, 2022, and for the three and nine months ended September 30, 2022 and 2021 are unaudited. The condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial information and on a basis consistent with the annual financial statements and, in the opinion of management, reflect all adjustments which include only normal recurring adjustments, necessary to present fairly its financial position as of September 30, 2022, results of operations for the three and nine months ended September 30, 2022 and 2021, and cash flows for the nine months ended September 30, 2022 and 2021. The results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ended December 31, 2022 or for any other interim period or for any other future year. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 29, 2022. (b) Liquidity Going Concern We have incurred net losses and negative cash flows from operations since our inception and had an accumulated deficit of approximately $137.6 million as of September 30, 2022. Management expects operating losses and negative cash flows to continue through at least the next several years. We expect to incur increasing costs as we advance our trials and development activities. Therefore, absent additional funding, management believes cash and cash equivalents of approximately $6.7 million as of September 30, 2022 are not sufficient to fund the Company’s planned expenditures and meet its obligations beyond April 2023. These factors raise substantial doubt about the Company’s ability to continue as a going concern beyond one year from the date these financial statements are issued. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s ability to continue as a going concern and to continue further development of its therapeutic candidates beyond April 2023, will require the Company to raise additional capital. The Company plans to raise additional capital, potentially including debt and equity arrangements, to finance its future operations. While management believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt, these plans are not entirely within its control and cannot be assessed as being probable of occurring. If adequate funds are not available, we may be required to reduce operating expenses, delay or reduce the scope of our product development programs, obtain funds through arrangements with others that may require us to relinquish rights to certain of our technologies or products that we would otherwise seek to develop or commercialize, or cease operations. (c) Use of Estimates The preparation of the financial statements in accordance with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include share-based compensation, the useful lives of property and equipment, right-of-use assets and related liabilities, incremental borrowing rate, allowances for doubtful accounts and sales returns, clinical accruals and assumptions used for revenue recognition. (d) Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, BioCardia Lifesciences, Inc. All intercompany accounts and transactions have been eliminated during the consolidation process. (e) Changes to Significant Accounting Policies The Company’s significant accounting policies are described in Note 2 of the notes to the consolidated financial statements included in its Annual Report on Form 10-K filed March 29, 2022 for the year ended December 31, 2021. There have been no changes to those policies. (f) Recent Accounting Pronouncements Recent accounting pronouncements issued by the Financial Accounting Standards Board (FASB), including its Emerging Issues Task Force did not or are not believed by management to have a material impact on our financial statement presentation or disclosures.

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurement	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Fair Value Disclosures [Text Block]	(3) Fair Value Measurement The fair value of financial instruments reflects the amounts that we estimate to receive in connection with the sale of an asset or paid in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). We follow a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into the following three levels: Level 1 – quoted prices in active markets for identical assets and liabilities. Level 2 – observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The following table sets forth the fair value of its financial assets measured on a recurring basis as of September 30, 2022 and December 31, 2021 and indicates the fair value hierarchy utilized to determine such fair value (in thousands): As of September 30, 2022 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 6,292 $ — $ — $ 6,292 Cash in checking account — — — 375 Total cash and cash equivalents $ 6,292 $ — $ — $ 6,667 As of December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 12,917 $ — $ — $ 12,917 Cash in checking account — — — (45 ) Total cash and cash equivalents $ 12,917 $ — $ — $ 12,872

Note 4 - Property and Equipment

Note 4 - Property and Equipment, Net	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	(4) Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): September 30, December 31, 2022 2021 Computer equipment and software $ 157 $ 133 Laboratory and manufacturing equipment 575 460 Furniture and fixtures 27 26 Leasehold improvements 26 26 Construction in progress 2 74 Property and equipment, gross 787 719 Less accumulated depreciation (598 ) (537 ) Property and equipment, net $ 189 $ 182 Depreciation expense totaled $29,000 and $61,000 for the three and nine months ended September 30, 2022, respectively. Depreciation expense totaled $15,000 and $45,000 for the three and nine months ended September 30, 2021, respectively.

Note 5 - Operating Lease Right-

Note 5 - Operating Lease Right-of-use Asset, Net	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	(5) Operating Lease Right-of-Use Asset, Net Our operating lease related to a property lease for our laboratory and corporate offices expired in December 2021, and we entered into a new lease which expires in January 2027, with an option for us to extend a further 36 months after expiration. Our lease agreements do not contain any material residual guarantees or material restrictive covenants. We determine if an arrangement is a lease at inception by assessing whether it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Right-of-use (ROU) assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The Company’s lease does not provide an implicit rate. We used an adjusted historical incremental borrowing rate, based on the information available at the approximate lease commencement date, to determine the present value of lease payments. Variable rent expense is made up of expenses for common area maintenance and shared utilities and were not included in the determination of the present value of lease payments. We have no finance leases. Our lease expense for the three and nine months ended September 30, 2022 was $121,000 and $362,000, respectively. Our lease expense for the three and nine months ended September 30, 2021 was $150,000 and $451,000, respectively. The cash paid under the operating lease for base rent for the three and nine months ended September 30, 2022 was $114,000 and $287,000, respectively. The cash paid under the operating lease during the three and nine months ended September 30, 2021 was $162,000 and $486,000, respectively. On September 30, 2022, the weighted average remaining lease term was 4.34 years, and the weighted average discount rate was 10.74%. Future minimum lease payments under the operating lease as of September 30, 2022 were as follows (in thousands): Remainder of 2022 $ 114 2023 471 2024 485 2025 499 2026 514 2027 44 Total undiscounted lease payments 2,127 Less imputed interest 425 Total operating lease liabilities $ 1,702

Note 6 - Accrued Expenses and O

Note 6 - Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Accrued Liabilities and Other Current Liabilities Disclosure [Text Block]	(6) Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): September 30, December 31, 2022 2021 Accrued expenses $ 115 $ 240 Accrued salaries and employee benefits 988 861 Accrued clinical trial costs 352 334 Grant liability 556 590 Customer deposits 90 96 Payable to related party 14 — Total $ 2,115 $ 2,121

Note 7 - Stockholders' Equity

Note 7 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	(7) Stockholders Equity Warrants Number of Weighted Common Stock Average Warrants Exercise Price Balance as of December 31, 2021 2,424,724 $ 6.36 Warrants for common stock sold — — Warrants for common stock exercised — — Balance as of September 30, 2022 2,424,724 $ 6.36 Lincoln Park Capital stock purchase agreement - Pursuant to the Purchase Agreement, in March 2021, Lincoln Park purchased 373,832 shares of common stock, at a price of $5.35 per share, for a total gross purchase price of $2 million (the Initial Purchase) and the Company issued 80,000 shares of common stock as commitment shares, which included 5,000 commitment shares issued on a pro rata basis for the initial $2 million purchase. As of September 30, 2022, the Company had not sold any common stock to Lincoln Park under the Purchase Agreement other than the Initial Purchase. Cantor Fitzgerald Sales agreement - During the three months ended September 30, 2022, the Company sold 66,704 shares of common stock under the ATM Offering at then-market prices for total gross proceeds of $139,000, with a net refund of issuance costs of $1,000. During the nine months ended September 30, 2022, the Company sold 641,704 shares of common stock under the ATM Offering at then-market prices for total gross proceeds of approximately $1.7 million, with associated issuance costs of $231,000.

Note 8 - Share-based Compensati

Note 8 - Share-based Compensation	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	(8) Share-Based Compensation The share-based compensation expense is recorded in research and development, and selling, general and administrative expenses based on the employee's or non-employee’s respective function. No share-based compensation was capitalized during the periods presented. Share-based compensation expense for the three and nine months ended September 30, 2022 and 2021 was recorded as follows (in thousands): Three months ended Nine months ended September 30, September 30, 2022 2021 2022 2021 Research and development $ 132 $ 196 $ 389 $ 613 Selling, general and administrative 148 241 514 624 Total share-based compensation $ 280 $ 437 $ 903 $ 1,237 The following table summarizes the activity of stock options and related information: Options outstanding Number of shares Weighted average exercise price Weighted average remaining contractual term (years) Aggregate intrinsic value (in thousands) Balance, December 31, 2021 1,649,686 $ 5.00 7.6 $ — Stock options granted 603,953 1.54 Stock options exercised — Stock options forfeited (101,796 ) 3.77 Stock options expired (3,111 ) 9.55 Balance, September 30, 2022 2,148,732 $ 4.08 7.7 $ 248 Exercisable, September 30, 2022 1,052,136 $ 5.70 6.5 $ 22 Unrecognized share-based compensation for employee and nonemployee options granted through September 30, 2022 is approximately $2.3 million to be recognized over a remaining weighted average service period of 2.6 years. Share-Based Compensation (RSUs) The following summarizes the activity of non-vested RSUs: Weighted average grant date Number of fair value shares per share Balance, December 31, 2021 200,271 $ 4.13 RSUs granted 269,204 1.49 RSUs released (328,958 ) 2.72 RSUs forfeited (87,718 ) 1.49 Balance, September 30, 2022 52,799 $ 3.81 RSUs vested and settled are converted into the Company’s common stock on a one-for-one basis. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. Of the 52,799 RSUs outstanding on September 30, 2022, 50,065 RSUs are vested and have not been settled and 2,734 have not yet vested. The related compensation expense, which is based on the grant date fair value of the Company’s common stock multiplied by the number of units granted, is recognized ratably over the period during which the vesting restrictions lapse. Unrecognized share-based compensation for employee and nonemployee RSUs granted through September 30, 2022 is approximately $7,000 to be recognized over a remaining weighted average service period of 0.6 years.

Note 9 - Net Loss Per Share

Note 9 - Net Loss Per Share	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Earnings Per Share [Text Block]	(9) Net Loss per Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding and fully vested restricted stock units. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Common stock equivalents are comprised of unvested restricted stock units, warrants to purchase common stock and options outstanding under the stock option plans. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding since the effects of potentially dilutive securities are antidilutive due to the net loss position. The following outstanding common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: September 30, 2022 2021 Stock options to purchase common stock 2,148,732 1,684,066 Unvested restricted stock units 2,734 5,468 Common stock warrants 2,424,724 2,424,724 Total 4,576,190 4,114,258

Note 10 - Income Taxes

Note 10 - Income Taxes	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Income Tax Disclosure [Text Block]	(10) Income Taxes During the three and nine months ended September 30, 2022 and 2021, there was no income tax expense or benefit for federal or state income taxes in the accompanying condensed consolidated statements of operations due to the Company’s net loss and a full valuation allowance on the resulting deferred tax assets. As of September 30, 2022, the Company retains a full valuation allowance on its deferred tax assets in all jurisdictions. The realization of its deferred tax assets depends primarily on its ability to generate future taxable income which is uncertain. The Company does not believe that its deferred tax assets are realizable on a more-likely-than-not basis; therefore, the net deferred tax assets have been fully offset by a valuation allowance.

Note 11 - Related Party Transac

Note 11 - Related Party Transactions	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	(11) Related Party Transactions On April 9, 2020, the Company entered into a Litigation Funding Agreement (the Funding Agreement) with BSLF, L.L.C. (the Funder), an entity owned and controlled by Andrew Blank, Chair of BioCardia’s board of directors, for the purpose of funding the Company’s legal proceedings and any and all claims, actions and/or proceedings relating to or arising from the case captioned Boston Scientific Corp., et al., v. BioCardia Inc., Case No. 3:19-05645-VC, U.S.D.C., N. D. Cal (the Litigation). On April 12, 2021, all parties to the Litigation entered into a confidential settlement agreement and all claims were dismissed. In March 2022, the Company entered into settlement agreements with its litigation service providers and the Funder to terminate the Funding Agreement and conclude on all remaining matters thereunder (the Litigation Funding Settlement). Under the terms of the confidential agreements, litigation and corporate counsel provided credits and refunds of legal fees totaling $ 688,000,

Note 12 - Contingencies and Unc

Note 12 - Contingencies and Uncertainties	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Contingencies Disclosure [Text Block]	(12) Contingencies and Uncertainties Contingencies Uncertainties

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	(a) Basis of Preparation The accompanying condensed consolidated balance sheets, statements of operations, stockholders’ equity, and cash flows as of September 30, 2022, and for the three and nine months ended September 30, 2022 and 2021 are unaudited. The condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial information and on a basis consistent with the annual financial statements and, in the opinion of management, reflect all adjustments which include only normal recurring adjustments, necessary to present fairly its financial position as of September 30, 2022, results of operations for the three and nine months ended September 30, 2022 and 2021, and cash flows for the nine months ended September 30, 2022 and 2021. The results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ended December 31, 2022 or for any other interim period or for any other future year. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 29, 2022.
Going Concern and Liquidity [Policy Text Block]	(b) Liquidity Going Concern We have incurred net losses and negative cash flows from operations since our inception and had an accumulated deficit of approximately $137.6 million as of September 30, 2022. Management expects operating losses and negative cash flows to continue through at least the next several years. We expect to incur increasing costs as we advance our trials and development activities. Therefore, absent additional funding, management believes cash and cash equivalents of approximately $6.7 million as of September 30, 2022 are not sufficient to fund the Company’s planned expenditures and meet its obligations beyond April 2023. These factors raise substantial doubt about the Company’s ability to continue as a going concern beyond one year from the date these financial statements are issued. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s ability to continue as a going concern and to continue further development of its therapeutic candidates beyond April 2023, will require the Company to raise additional capital. The Company plans to raise additional capital, potentially including debt and equity arrangements, to finance its future operations. While management believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt, these plans are not entirely within its control and cannot be assessed as being probable of occurring. If adequate funds are not available, we may be required to reduce operating expenses, delay or reduce the scope of our product development programs, obtain funds through arrangements with others that may require us to relinquish rights to certain of our technologies or products that we would otherwise seek to develop or commercialize, or cease operations.
Use of Estimates, Policy [Policy Text Block]	(c) Use of Estimates The preparation of the financial statements in accordance with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include share-based compensation, the useful lives of property and equipment, right-of-use assets and related liabilities, incremental borrowing rate, allowances for doubtful accounts and sales returns, clinical accruals and assumptions used for revenue recognition.
Consolidation, Policy [Policy Text Block]	(d) Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, BioCardia Lifesciences, Inc. All intercompany accounts and transactions have been eliminated during the consolidation process.
Change to Significant Accounting Policies [Policy Text Block]	(e) Changes to Significant Accounting Policies The Company’s significant accounting policies are described in Note 2 of the notes to the consolidated financial statements included in its Annual Report on Form 10-K filed March 29, 2022 for the year ended December 31, 2021. There have been no changes to those policies.
New Accounting Pronouncements, Policy [Policy Text Block]	(f) Recent Accounting Pronouncements Recent accounting pronouncements issued by the Financial Accounting Standards Board (FASB), including its Emerging Issues Task Force did not or are not believed by management to have a material impact on our financial statement presentation or disclosures.

Note 3 - Fair Value Measureme_2

Note 3 - Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	As of September 30, 2022 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 6,292 $ — $ — $ 6,292 Cash in checking account — — — 375 Total cash and cash equivalents $ 6,292 $ — $ — $ 6,667 As of December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 12,917 $ — $ — $ 12,917 Cash in checking account — — — (45 ) Total cash and cash equivalents $ 12,917 $ — $ — $ 12,872

Note 4 - Property and Equipme_2

Note 4 - Property and Equipment, Net (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Property, Plant and Equipment [Table Text Block]	September 30, December 31, 2022 2021 Computer equipment and software $ 157 $ 133 Laboratory and manufacturing equipment 575 460 Furniture and fixtures 27 26 Leasehold improvements 26 26 Construction in progress 2 74 Property and equipment, gross 787 719 Less accumulated depreciation (598 ) (537 ) Property and equipment, net $ 189 $ 182

Note 5 - Operating Lease Righ_2

Note 5 - Operating Lease Right-of-use Asset, Net (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Remainder of 2022 $ 114 2023 471 2024 485 2025 499 2026 514 2027 44 Total undiscounted lease payments 2,127 Less imputed interest 425 Total operating lease liabilities $ 1,702

Note 6 - Accrued Expenses and_2

Note 6 - Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Accrued Liabilities and Other Current Liabilities [Table Text Block]	September 30, December 31, 2022 2021 Accrued expenses $ 115 $ 240 Accrued salaries and employee benefits 988 861 Accrued clinical trial costs 352 334 Grant liability 556 590 Customer deposits 90 96 Payable to related party 14 — Total $ 2,115 $ 2,121

Note 7 - Stockholders' Equity (

Note 7 - Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Weighted Common Stock Average Warrants Exercise Price Balance as of December 31, 2021 2,424,724 $ 6.36 Warrants for common stock sold — — Warrants for common stock exercised — — Balance as of September 30, 2022 2,424,724 $ 6.36

Note 8 - Share-based Compensa_2

Note 8 - Share-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Share-based Compensation, Expense [Table Text Block]	Three months ended Nine months ended September 30, September 30, 2022 2021 2022 2021 Research and development $ 132 $ 196 $ 389 $ 613 Selling, general and administrative 148 241 514 624 Total share-based compensation $ 280 $ 437 $ 903 $ 1,237
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Options outstanding Number of shares Weighted average exercise price Weighted average remaining contractual term (years) Aggregate intrinsic value (in thousands) Balance, December 31, 2021 1,649,686 $ 5.00 7.6 $ — Stock options granted 603,953 1.54 Stock options exercised — Stock options forfeited (101,796 ) 3.77 Stock options expired (3,111 ) 9.55 Balance, September 30, 2022 2,148,732 $ 4.08 7.7 $ 248 Exercisable, September 30, 2022 1,052,136 $ 5.70 6.5 $ 22
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Weighted average grant date Number of fair value shares per share Balance, December 31, 2021 200,271 $ 4.13 RSUs granted 269,204 1.49 RSUs released (328,958 ) 2.72 RSUs forfeited (87,718 ) 1.49 Balance, September 30, 2022 52,799 $ 3.81

Note 9 - Net Loss Per Share (Ta

Note 9 - Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	September 30, 2022 2021 Stock options to purchase common stock 2,148,732 1,684,066 Unvested restricted stock units 2,734 5,468 Common stock warrants 2,424,724 2,424,724 Total 4,576,190 4,114,258

Note 2 - Significant Accounti_2

Note 2 - Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Retained Earnings (Accumulated Deficit), Total	$ (137,576)	$ 137,600	$ (128,697)
Cash and Cash Equivalents, at Carrying Value, Total	$ 6,667	$ 6,700	$ 12,872

Note 3 - Fair Value Measureme_3

Note 3 - Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Money market funds	$ 6,667	$ 12,872
Cash and Cash Equivalents, Fair Value	6,667	12,872
Fair Value, Inputs, Level 1 [Member]
Money market funds	6,292	12,917
Cash and Cash Equivalents, Fair Value	6,292	12,917
Fair Value, Inputs, Level 2 [Member]
Money market funds	0	0
Cash and Cash Equivalents, Fair Value	0	0
Fair Value, Inputs, Level 3 [Member]
Money market funds	0	0
Cash and Cash Equivalents, Fair Value	0	0
Money Market Funds [Member]
Money market funds	6,292	12,917
Cash and Cash Equivalents, Fair Value	6,292	12,917
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Money market funds	6,292	12,917
Cash and Cash Equivalents, Fair Value	6,292	12,917
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Money market funds	0	0
Cash and Cash Equivalents, Fair Value	0	0
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Money market funds	0	0
Cash and Cash Equivalents, Fair Value	0	0
Demand Deposits [Member]
Money market funds	375	45
Cash and Cash Equivalents, Fair Value	375	45
Demand Deposits [Member] | Fair Value, Inputs, Level 1 [Member]
Money market funds	0	0
Cash and Cash Equivalents, Fair Value	0	0
Demand Deposits [Member] | Fair Value, Inputs, Level 2 [Member]
Money market funds	0	0
Cash and Cash Equivalents, Fair Value	0	0
Demand Deposits [Member] | Fair Value, Inputs, Level 3 [Member]
Money market funds	0	0
Cash and Cash Equivalents, Fair Value	$ 0	$ 0

Note 4 - Property and Equipme_3

Note 4 - Property and Equipment, Net (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Depreciation, Total	$ 29,000	$ 15,000	$ 61,000	$ 45,000

Note 4 - Property and Equipme_4

Note 4 - Property and Equipment, Net - Summary of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Property and equipment, gross	$ 787	$ 719
Less accumulated depreciation	(598)	(537)
Property and equipment, net	189	182
Computer Equipment and Software [Member]
Property and equipment, gross	157	133
Laboratory and Manufacturing Equipment [Member]
Property and equipment, gross	575	460
Furniture and Fixtures [Member]
Property and equipment, gross	27	26
Leasehold Improvements [Member]
Property and equipment, gross	26	26
Construction in Progress [Member]
Property and equipment, gross	$ 2	$ 74

Note 5 - Operating Lease Righ_3

Note 5 - Operating Lease Right-of-use Asset, Net (Details Textual) - USD ($)	3 Months Ended				9 Months Ended
	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating Lease, Expense		$ 121,000	$ 150,000	$ 362,000		$ 451,000
Operating Lease, Payments	$ 114,000	$ 162,000		$ 486,000	$ 287,000
Operating Lease, Weighted Average Remaining Lease Term (Year)		4 years 4 months 2 days
Operating Lease, Weighted Average Discount Rate, Percent		10.74%

Note 5 - Operating Lease Righ_4

Note 5 - Operating Lease Right-of-use Asset, Net - Future Minimum Lease Payments Under Operating Lease (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Remainder of 2022	$ 114
2023	471
2024	485
2025	499
2026	514
2027	44
Total undiscounted lease payments	2,127
Less imputed interest	425
Total operating lease liabilities	$ 1,702

Note 6 - Accrued Expenses and_3

Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Accrued expenses	$ 115,000	$ 240,000
Accrued salaries and employee benefits	988,000	861,000
Accrued clinical trial costs	352,000	334,000
Grant liability	556,000	590,000
Customer deposits	90,000	96,000
Payable to Related Party	14,000	0
Total	$ 2,115,000	$ 2,121,000

Note 7 - Stockholders' Equity_2

Note 7 - Stockholders' Equity (Details Textual) - USD ($)				3 Months Ended	9 Months Ended
	Apr. 12, 2022	Mar. 29, 2021	Sep. 04, 2019	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021
Proceeds from Issuance of Common Stock					$ 1,658,000	$ 2,001,000
Payments of Stock Issuance Costs					$ 231,000	$ 59,000
Underwriters [Member]
Stock Issued During Period, Shares, New Issues			80,000
Purchase Agreement with Lincoln Park [Member]
Sale of Stock, Aggregate Value, Maximum		$ 20,000,000
Stock Issued During Period, Shares, New Issues		373,832
Shares Issued, Price Per Share		$ 5.35
Proceeds from Issuance of Common Stock		$ 2,000,000
Stock Issued During the Period, Shares, Commission Fees		80,000
Stock Issued During the Period, Commitment Shares Issued on Pro Rata Basis		5,000
Stock Issuable, Commitment Shares on Pro Rata Basis		5,000
Sales Agreement with Cantor Fitzgerald Co (Cantor) [Member]
Sale of Stock, Aggregate Value, Maximum	$ 10,500,000
Stock Issued During Period, Shares, New Issues				66,704	641,704
Proceeds from Issuance of Common Stock				$ 139,000	$ 1,700,000
Accrued Sales Commission, Current, Percentage	3%
Payments of Stock Issuance Costs				$ 1,000	$ 231,000

Note 7 - Stockholders' Equity -

Note 7 - Stockholders' Equity - Warrants (Details)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Balance, beginning (in shares) | shares	2,424,724
Balance, beginning, weighted average exercise price (in dollars per share) | $ / shares	$ 6.36
Warrants for common stock sold (in shares) | shares	0
Warrants for common stock sold, weighted average exercise price (in dollars per share) | $ / shares	$ 0
Warrants for common stock exercised (in shares) | shares	0
Warrants for common stock exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 0
Balance, ending (in shares) | shares	2,424,724
Balance, ending, weighted average exercise price (in dollars per share) | $ / shares	$ 6.36

Note 8 - Share-based Compensa_3

Note 8 - Share-based Compensation (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount	$ 7,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	7 months 6 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period	328,958
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance	52,799	200,271
Non-employee Directors and Employees [Member]
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount	$ 2,300,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	2 years 7 months 6 days
Non-employee Directors and Employees [Member] | Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance (in shares)	52,799
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period	50,065
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance	2,734

Note 8 - Share-based Compensa_4

Note 8 - Share-based Compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Total share-based compensation	$ 280	$ 437	$ 903	$ 1,237
Research and Development Expense [Member]
Total share-based compensation	132	196	389	613
Selling, General and Administrative Expenses [Member]
Total share-based compensation	$ 148	$ 241	$ 514	$ 624

Note 8 - Share-based Compensa_5

Note 8 - Share-based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Stock options outstanding, beginning of period (in shares)	1,649,686
Balance, weighted average exercise price, beginning of period (in dollars per share)	$ 5
Stock options outstanding, weighted average remaining contractual term (Year)	7 years 8 months 12 days	7 years 7 months 6 days
Stock options outstanding, aggregate intrinsic value	$ 248	$ 0
Stock options granted (in shares)	603,953
Stock options granted, weighted average exercise price (in dollars per share)	$ 1.54
Stock options exercised (in shares)	0
Stock options forfeited (in shares)	(101,796)
Stock options forfeited, weighted average exercise price (in dollars per share)	$ 3.77
Stock options expired (in shares)	(3,111)
Stock options expired, weighted average exercise price (in dollars per share)	$ 9.55
Balance, March 31, 2022 (in shares)	2,148,732	1,649,686
Balance, weighted average exercise price, beginning of period (in dollars per share)	$ 4.08	$ 5
Exercisable, March 31, 2022 (in shares)	1,052,136
Options exercisable, weighted average exercise price (in dollars per share)	$ 5.70
Options exercisable, weighted average remaining contractual term (Year)	6 years 6 months

Note 8 - Share-based Compensa_6

Note 8 - Share-based Compensation - Stock Option Activity-parentheticals (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value	$ 22

Note 8 - Share-based Compensa_7

Note 8 - Share-based Compensation - Summary of Non-vested RSUs (Details)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
RSUs granted, weighted average grant date fair value per share (in dollars per share) | $ / shares	$ 1.49
RSUs released, weighted average grant date fair value per share (in dollars per share) | $ / shares	2.72
RSUs forfeited, weighted average grant date fair value per share (in dollars per share) | $ / shares	1.49
Balance, weighted average grant date fair value per share (in dollars per share) | $ / shares	$ 3.81
Restricted Stock Units (RSUs) [Member]
Balance, shares (in shares) | shares	200,271
Balance, weighted average grant date fair value per share (in dollars per share) | $ / shares	$ 4.13
RSUs granted, shares (in shares) | shares	269,204
RSUs released, shares (in shares) | shares	(328,958)
RSUs forfeited, shares (in shares) | shares	(87,718)
Balance, shares (in shares) | shares	52,799

Note 9 - Net Loss Per Share - A

Note 9 - Net Loss Per Share - Anti-dilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Antidilutive securities (in shares)	4,576,190	4,114,258
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	2,148,732	1,684,066
Restricted Stock Units (RSUs) [Member]
Antidilutive securities (in shares)	2,734	5,468
Warrant [Member]
Antidilutive securities (in shares)	2,424,724	2,424,724

Note 11 - Related Party Trans_2

Note 11 - Related Party Transactions (Details Textual) - USD ($)		1 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 17, 2022	Mar. 29, 2022	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2021
Due to Related Parties, Current, Total			$ 14,000	$ 14,000	$ 0
BSLF, L.L.C. [Member] | Funding Agreement [Member]
Legal Fees		$ 688,000
Maximum Discount on Legal Service		$ 300,000
Increase (Decrease) in Accounts Payable, Related Parties					(523,000)
Due from Related Parties, Total					562,000
Related Party Transaction, Amounts of Transaction	$ 156,000
Litigation Service, Expense			$ 14,000	$ 61,000
BSLF, L.L.C. [Member] | Funding Agreement [Member] | Accrued Expenses and Other Current Liabilities [Member]
Accounts Payable, Related Parties					$ 156,000